IOVA Iovance Biotherapeutics Inc: Enterprise Value-to-Revenue Multiple

Public company logo of iovance.com (IOVA)

Scaling the network of medical centers reduces the production costs of personalized medicines, creating strong operating leverage for Iovance Biotherapeutics (IOVA). The EV/Sales multiple reflects the current market valuation, with the latest mark standing at 8051.57. While its leadership status in T-cell therapy earns Iovance Biotherapeutics (IOVA) the trust of physicians, fierce competition with biotech behemoths and the risk of cheaper generics pose significant challenges for the business.

Company Value to Revenue: Iovance Biotherapeutics Inc (IOVA) for 11/23/2025 - 11/20/2026

iovance.com - analytical breakdowns and key metrics (IOVA)

- share price and consensus valuation forecast:
Initial company analysis:Iovance Biotherapeutics IOVA
Product sample of Iovance Biotherapeutics

For Iovance Biotherapeutics (IOVA), the expansion of clean room capacities directly impacts future revenue, making the EV/Sales analysis critically important. This metric compares the enterprise value of the business, including net debt, against annual sales volume. Analyzing the business valuation via EV/Sales allows for the determination of whether the asset is overbought relative to its historical trend. It is vital for investors to avoid entering at the peak of the valuation cycle. Effective re-equipping of production lines should lead to an organic decrease in this ratio.

Competitor analysis for Iovance Biotherapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IMTX|EV/Sales Multiple XNCR (Xencor)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP